To the Editor: The article “ Dabigatran: Will it change clinical practice ”1 has a dangerous error. In its Key Points, it says “dabigatran is a potent, reversible direct thrombin inhibitor.” In fact, it is not reversible. 2
Shamefully poor editing.
Letters To The Editor
Dabigatran
Cleveland Clinic Journal of Medicine. 2011 December;78(12):787
Author(s):
Van Smith, MD, FACP
Author and Disclosure Information
Van Smith, MD, FACP
Next Article:
Related Articles
-
-
Current Drug Therapy
Dabigatran: Will it change clinical practice?
- Author:
- Siddharth A. Wartak, MD
- John R. Bartholomew, MD, FACC
This new oral anticoagulant has advantages over warfarin (Coumadin), but it is more expensive, which may pose a barrier to its wider use.